SEK 25 million to ENABLE-2 and continued development of new antibiotics
ENABLE, the EU initiative for antibiotic development led by Uppsala University, has received SEK 25 million from the Swedish Research Council to start up ENABLE-2. "We are already accepting project proposals and hope that this investment will inspire more financiers," says coordinator Anders Karlén.
The Swedish Research Council allocated SEK 25 million to ENABLE-2, a national extension of the EU project ENABLE – European Gram-Negative Antibacterial Engine, that will be coordinated via Uppsala University's Faculty of Pharmacy. The grant is part of the SEK 100 million that the Swedish government is investing in the national research program on antibiotic resistance. The initiative has been warmly welcomed by Anders Karlén, coordinator of ENABLE-2 and Professor of Computer-aided drug design at Uppsala University:
“The development of new antibiotics is a central part of the efforts to address the problems arising from resistant bacteria. To succeed we need sufficient resources to provide support during the early stages of antibacterial drug development. With ENABLE, we have built a successful foundation, and the Swedish Research Council's continued trust in our work gives us the conditions we need to continue developing what we have begun,” says Anders Karlén.
ENABLE-2 is already accepting applications from researchers with molecules that can be candidates for antibacterial drugs. This call is initially aimed at Swedish academia and biotech industry and the initial application period will remain open until 31 October. The platform has funding through 2022, but ambitions are to operate in a longer perspective and to develop collaborations with funders and research environments in other European countries.
“We have chosen to prioritise the early stages of discovery and development of antibiotics, a phase where we have identified a great need for project support along the way towards new antibacterial drugs. This applies in particular to support for antibacterial agents for systemic use against specially problematic pathogens, with the aim to advance the best of these Hit compounds to a level where they can be successfully taken up by other global initiatives or out-licensed,” says Anders Karlén.
ENABLE was initiated in collaboration between the EU and the European pharmaceutical industry with the aim of taking a drug candidate all the way to human testing. The project wrapped up in October 2021, and during its 7.5 years, several potential antibiotic molecules have been developed with one candidate drug undergoing a phase I study with positive results. Uppsala University's Faculties of Pharmacy and Medicine have contributed expertise in, among other things, medicinal chemistry, microbiology, ADME and project coordination, all valuable contributions that have helped in consolidating Uppsala's already advanced position in the field of antibiotics.
“Since November 2019, Uppsala University also has a leading role in COMBINE, one of eight projects in the IMI AMR Accelerator where the EU and the pharmaceutical industry are working with a common goal to within six years produce ten new preclinical drug candidates, of which five will be able to achieve phase 2 studies. Our work in ENABLE has contributed to us today being able to mobilise all the experience and competence needed to take part in collaborations of this scope, and we are now seeing the evidence of the great reputation Uppsala University has built up in the field of antibiotics,” says Anders Karlén who also coordinates COMBINE.
- Is a national platform that offers project support for the development of antibacterial drugs.
- Is funded with SEK 25 million by the Swedish Research Council and coordinated at the Faculty of Pharmacy, Uppsala University.
- Is accepting applications until 31 October 2021.
- ENABLE-2 Expression of Interest (EoI) Ansökningsformulär
- AMR Accelerator
- Uppsala University in international initiative against tuberculosis
text: Magnus Alsne, photo: Mikael Wallerstedt, Uppsala University
SEK 25 million to ENABLE-2 and continued development of new antibiotics
2021-10-06ENABLE, the EU initiative for antibiotic development led by Uppsala University, has received SEK 25 million from the Swedish Research Council to start up ENABLE-2. "We are already accepting project proposals and hope that this investment will inspire...
MSI Lab Per Andrén joins SciLifeLab Spatial Omics
2021-09-16With the launch of national resource Spatial Omics, SciLifeLab consolidates Sweden's advanced position in one of the hottest fields of science. "This gives us the capacity to extract even more detailed knowledge from cell and tissue analyses," states...
Webinar about your possibilities at Testa Center
2021-09-14Testa Center provides Uppsala University’s researchers access to state-of-the-art equipment for drug and bioprocess development. At the webinar "Academic research in the Testa Center – A testing bed for upscaling your biological innovations", you w...
Andrea Benediktsdottir is awarded the Iris Scholarship for aspiring women
2021-08-13Andrea Benediktsdottir, PhD student at the Department of Medicinal Chemistry, is awarded the Iris Scholarship for aspiring women in Sweden. With the scholarship, Andrea Benediktsdottir will participate in an interdisciplinary course focusing on antib...
SciLifeLab – A national research infrastructure in Uppsala
2021-06-18SciLifeLab is a national research infrastructure in life sciences with Uppsala University as one of four host universities. Today, SciLifeLab conducts operations at most major Swedish universities. ...
New research to improve use of amphiphilic drug molecules
2021-05-19By exploring the aggregation properties of different amphiphilic molecules in microgels, Yassir Al-Tikriti, PhD student at the Department of Medicinal Chemistry, aims to provide tools and knowledge of importance for future cancer therapies and antide...
New seminar series puts focus on Swedish drug development
2021-04-19This spring semester, SweDeliver and NextBioForm invite to online lunch seminars. Welcome to experience frontline research with a focus on industrial challenges in drug delivery and the development of biologically based drugs. ...
Olof Eriksson receives SEK 1,3 million for PET project
2021-04-19Olof Eriksson, researcher in translational imaging, is awarded a Project Grant of SEK 1,303,000 from Diabetes Wellness Sweden for his project GPR44 as a PET marker for measuring beta cell mass in human. ...
New biomarkers can lead to breakthrough in diabetes research
2021-04-19With the discovery of two new biomarkers, Olof Eriksson, researcher in translational imaging, may lead the way to the scientific breakthrough that will enable curative drugs and personalised treatments for diabetes. ...
Apply for funding for postdoc exchange between the Faculty of Pharmacy and SLU
2021-04-19Funding is now available for two postdoc exchanges, one hosted by the Faculty of Pharmacy or Fauculty of Medicine at Uppsala University, and one by a department at the SLU Faculty of Veterinary Medicine and Animal Science ...
Here you can read more research news at the Department of Medicinal Chemistry